Please enable Javascript
Non-Muscle Invasive Urothelial Carcinoma
Advertisement
How Does Sasanlimab Fare in High-Risk, BCG-Naïve NMIBC?
Raj Satkunasivam, MD, MS, FRCSC
Non-Muscle Invasive Urothelial Carcinoma
|
September 8, 2023
Dr. Satkunasivam shares the inspiration for combining sasanlimab with BCG in patients with high-risk, BCG-naïve NMIBC.
View More
Dr. Sandip Prasad on ATLAS and ENVISION for Intermediate-Risk, Low-Grade NMIBC
Sandip Prasad, MD, MPhil
Non-Muscle Invasive Urothelial Carcinoma
|
August 30, 2023
Dr. Prasad provides overviews of ATLAS and ENVISION and opines on whether UGN-102 is a practice-ready alternative to TURBT.
View More
Exploring NMIBC Options in the Face of BCG Shortages, Failure
Leah Lawrence
Non-Muscle Invasive Urothelial Carcinoma
|
August 17, 2023
Several urologists weigh in on BCG, its role in NMIBC treatment, shortages, and strategies to treat BCG-unresponsive disease.
Read More
UGN-102 May Be Superior to TURBT for Managing Low-Grade, Intermediate-Risk NMIBC
Zachary Bessette
Non-Muscle Invasive Urothelial Carcinoma
|
August 8, 2023
The ATLAS study demonstrated the superiority of UGN-102 over TURBT for patients with low-grade, intermediate-risk NMIBC.
Read More
ATLAS, ENVISION Trials Demonstrate Benefit of UGN-102 for NMIBC
Emily Menendez
Non-Muscle Invasive Urothelial Carcinoma
|
August 4, 2023
UGN-102 is a sustained-release, hydrogel-based formula that allows bladder tissue to be exposed to mitomycin longer.
Read More
Predicting Differing Responses to Intravesical BCG Therapy for NMIBC
Emily Menendez
Non-Muscle Invasive Urothelial Carcinoma
|
July 10, 2023
Through molecular profiling, three different BCG response subtypes were found: BRS1, BRS2, and BRS3.
Read More
RESECT Study Results and Variations in NMIBC Recurrence Between Sites
Emily Menendez
ASCO 2023
|
June 1, 2023
An observational study sought to determine variation in recurrence after TURBT between sites taking part in the RESECT study.
Read More
FDA Approval of Adstiladrin Expands Options for Patients With BCG-Unresponsive NMIBC
Akhil Abraham Saji, MD
Non-Muscle Invasive Urothelial Carcinoma
|
May 30, 2023
FDA approval of Adstiladrin for use in BCG-unresponsive NMIBC expands the armamentarium for treatment of high-risk NMIBC.
Read More
Understanding the Financial Considerations and Treatment Costs Related to NMIBC
Akhil Abraham Saji, MD
Non-Muscle Invasive Urothelial Carcinoma
|
May 1, 2023
NMIBC-associated costs vary widely across types of treatments utilized, health systems, and regions of the country.
Read More
Global Variation in Early Recurrence After TURBT in the RESECT Study
Zachary Bessette
AUA 2023: Focus on Bladder Cancer
|
April 29, 2023
There is significant inter-site variation in recurrence of NMIBC after TRUBT in the RESECT study, according to new research.
Read More
Tolerability and Efficacy of BCG After NMIBC Recurrence Following Bladder-Preserving Therapy
Emily Menendez
AUA 2023: Focus on Bladder Cancer
|
April 28, 2023
Study results indicate an alternative strategy to radical cystectomy for comprehensive bladder-preserving therapy for MIBC.
Read More
Analyzing a New Treatment for Patients With NMIBC Who Failed BCG Therapy
Emily Menendez
Non-Muscle Invasive Urothelial Carcinoma
|
April 28, 2023
No nonsurgical treatments currently exist for patients with NMIBC who did not respond to BCG therapy.
Read More
Risk-Based Substratification Improves Surveillance Costs for Patients With HR-NMIBC
Emily Menendez
AUA 2023: Focus on Bladder Cancer
|
April 28, 2023
Patients with high-risk NMIBC who underwent TURBT from November 1993 to April 2019 were retrospectively evaluated.
Read More
PFS Is an Effective OS Surrogate for NMIBC
Emily Menendez
AUA 2023: Focus on Bladder Cancer
|
April 28, 2023
A study analyzed effect of time to progression on OS in a cohort of patients with HR-NMIBC treated with intravesical BCG.
Read More
Gemcitabine and Docetaxel May Be an Effective Alternative to BCG for High-Risk NMIBC
David Ambinder, MD
Non-Muscle Invasive Urothelial Carcinoma
|
April 26, 2023
Is there an alternative regimen to BCG for NMIBC? The combination of intravesical gemcitabine and docetaxel may be.
Read More
Addressing the BCG Shortage: Gemcitabine/Docetaxel Is an Effective Substitute Treatment for NMIBC
Vignesh Packiam, MD
Non-Muscle Invasive Urothelial Carcinoma
|
March 22, 2023
Vignesh T. Packiam, MD discusses the current BCG shortage as well as potential substitutes such as gemcitabine and docetaxel.
Read More
IFNα With Nadofaragene Firadenovec Shows Clinical Efficacy for NMIBC
Emily Menendez
Non-Muscle Invasive Urothelial Carcinoma
|
February 27, 2023
IFNα and nadofaragene firadenovec can provide a new therapy approach for a disease with a significant unmet clinical need.
Read More
IL-15 Superagonist for Treatment of BCG-unresponsive Non-muscle Invasive Bladder Cancer
Akhil Abraham Saji, MD
Non-Muscle Invasive Urothelial Carcinoma
|
February 24, 2023
BCG plus nogapendekin alfa inbakicept may offer an enhanced treatment option for patients with high-risk NMIBC.
Read More
KEYNOTE-057: Pembrolizumab Monotherapy for High-risk NMIBC Unresponsive to BCG
Andrea Necchi, MD
ASCO GU Symposium 2023
|
February 18, 2023
Andrea Necchi, MD, speculates on the applicability of pembrolizumab monotherapy for BCG-unresponsive NMIBC.
View More
Detecting MRD Prior to Repeat-transurethral Resection of Bladder Tumor in NMIBC
Kyle M. Rose, MD
ASCO GU Symposium 2023
|
February 18, 2023
Kyle M. Rose, MD, describes how cell-free DNA is used to detect MRD prior to repeat-transurethral resection in NMIBC.
View More
Load More
Advertisement
Advertisement
Advertisement